NCT02254785 - Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions

Metastatic Castration-Resistant Prostatic Cancer

Interventions

DRUG

cabazitaxel

Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression

DRUG

Abiraterone

Abiraterone 1000mg daily (oral) until disease progression

DRUG

Enzalutamide 160mg daily (oral)

Enzalutamide 160mg daily (oral) until disease progression

Trial Locations (15)

3000

Peter MacCallum Cancer Centre, Melbourne

3128

Box Hill Hospital, Box Hill

3168

Monash Health-Monash Medical Centre, Clayton

T2N 4N2

Tom Baker Cancer Cantre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V1Y 5J3

BCCA - Kelowna, Kelowna

V5Z 4E6

BCCA- Vancouver Center, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre, Hamilton

L1G 2B9

Durham Regional Cancer Centre (Lakeridge Health), Oshawa

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H3T 1E2

Jewish General Hospital, Montreal

27N 4H4

Saskatoon Cancer Center, Saskatoon